温通罐法治疗急性非特异性腰痛的疗效和脑网络调控机制研究

注册号:

Registration number:

ITMCTR2024000666

最近更新日期:

Date of Last Refreshed on:

2024-11-06

注册时间:

Date of Registration:

2024-11-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

温通罐法治疗急性非特异性腰痛的疗效和脑网络调控机制研究

Public title:

Study on the efficacy and brain network regulation mechanism of warm-tong cupping in the treatment of acute nonspecific low back pain

注册题目简写:

English Acronym:

研究课题的正式科学名称:

温通罐法治疗急性非特异性腰痛的疗效和脑网络调控机制研究

Scientific title:

Study on the efficacy and brain network regulation mechanism of warm-tong cupping in the treatment of acute nonspecific low back pain

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈昊

研究负责人:

王艳国

Applicant:

Hao Chen

Study leader:

Yanguo Wang

申请注册联系人电话:

Applicant telephone:

+86 151 2213 7302

研究负责人电话:

Study leader's telephone:

+86 137 5205 3466

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

how7302@163.com

研究负责人电子邮件:

Study leader's E-mail:

tjwangyanguo@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市河北区天津中医药大学第二附属医院

研究负责人通讯地址:

天津市河北区天津中医药大学第二附属医院

Applicant address:

Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

Study leader's address:

Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学第二附属医院

Applicant's institution:

Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024-032-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

天津中医药大学第二附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/9/25 0:00:00

伦理委员会联系人:

胡本泽

Contact Name of the ethic committee:

Benze Hu

伦理委员会联系地址:

天津市河北区增产道69号

Contact Address of the ethic committee:

No. 69 Zengchan Road Hebei District Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

02260637912

伦理委员会联系人邮箱:

Contact email of the ethic committee:

tjerc2013@126.com

研究实施负责(组长)单位:

天津中医药大学第二附属医院

Primary sponsor:

Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

研究实施负责(组长)单位地址:

天津市河北区增产道69号

Primary sponsor's address:

No. 69 Zengchan Road Hebei District Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第二附属医院

具体地址:

天津市河北区增产道69号

Institution
hospital:

Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

Address:

No. 69, Zengchan Road, Hebei District, Tianjin

经费或物资来源:

科室自筹经费

Source(s) of funding:

Department self-raised funds

研究疾病:

急性非特异性腰痛

研究疾病代码:

Target disease:

acute non-specific low back pain(ANSLBP)

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

在揭示腰背肌生物力学和形态学特征的基础上,阐释温通罐疗法对急性非特异性腰痛患者的脑网络调控机制。

Objectives of Study:

On the basis of revealing the biomechanical and morphological characteristics of the lumbar and back muscles the brain network regulatory mechanism of Wentong Guan therapy in patients with acute nonspecific low back pain is explained.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

温通罐及药物组: (1)符合ANSLBP诊断标准,腰部疼痛发生<6周; (2)年龄18-75岁,右利手; (3)近一周平均疼痛视觉模拟评分 (Visual Analogue Scale, VAS)≥3分; (4)近一月内未接受其他针对本病的相关治疗; (5)无椎间盘摘除手术及其他相关手术史; (6)自愿接受并配合本研究治疗方案,签署知情同意书。 健康对照组: (1)年龄 18~75 岁,右利手; (2)无急、慢性下腰痛病史; (3)入组前至少 1 个月无任何疾病引起的疼痛史且未接受过任何与疼痛相关的治疗; (4)签署知情同意书。

Inclusion criteria

WTG cupping and medication group: (1) Meets the ANSLBP diagnostic criteria with lower back pain occurring<6 weeks; (2) Age 18-75 years old right-handed; (3) The average Visual Analog Scale (VAS) score for pain in the past week is ≥ 3 points; (4) Not receiving any other relevant treatment for this disease within the past month; (5) No history of intervertebral disc removal surgery or other related surgeries; (6) Voluntarily accept and cooperate with the treatment plan of this study and sign an informed consent form. Healthy control group: (1) Age 18-75 years old right-handed; (2) No history of acute or chronic lower back pain; (3) At least one month prior to enrollment there should be no history of pain caused by any illness and no treatment related to pain has been received; (4) Sign the informed consent form.

排除标准:

(1)患有脊柱侧弯、强直性脊柱炎、骨结核、肿瘤、严重骨质疏松等骨科疾病,或近1个月有其他疾病引发的急性疼痛史; (2)严重脊柱外伤及脊柱手术史; (3)接触性过敏、艾烟过敏或洛索洛芬钠片过敏; (4)操作部位皮肤有破损、过敏、感染等不适宜进行温通罐治疗的情况; (5)头颅畸形、头皮破损无法佩戴头帽或预采集信号不佳者; (6)患有自身免疫性疾病、过敏性疾病、急慢性传染病,或合并心脑血管、血液系统、消化系统等严重内科或精神疾病; (7)近一周同时参加其他临床研究者。

Exclusion criteria:

(1)Suffering from scoliosis ankylosing spondylitis bone tuberculosis tumors severe osteoporosis and other orthopedic diseases or a history of acute pain caused by other diseases in the past month; (2)History of severe spinal trauma and spinal surgery; (3)Contact allergy moxa smoke allergy or loxoprofen sodium tablet allergy; (4)The skin at the operation site is damaged allergic infected etc. which is not suitable for WTG; (5)Individuals with head deformities scalp damage inability to wear headgear or poor fNIRS signals in pre-acquisition; (6)Suffering from autoimmune diseases allergic diseases acute or chronic infectious diseases or serious medical or mental diseases such as cardiovascular hematological and digestive system diseases; (7)Who participated in other clinical research simultaneously in the past week.

研究实施时间:

Study execute time:

From 2024-08-14

To      2025-06-30

征募观察对象时间:

Recruiting time:

From 2024-11-10

To      2024-12-31

干预措施:

Interventions:

组别:

药物对照组

样本量:

30

Group:

Drug control group

Sample size:

干预措施:

口服洛索洛芬钠

干预措施代码:

Intervention:

Oral loxoprofen sodium

Intervention code:

组别:

温通罐组

样本量:

30

Group:

Patient Group

Sample size:

干预措施:

进行1次温通罐治疗

干预措施代码:

Intervention:

One time of warming cupping treatment

Intervention code:

组别:

健康志愿者

样本量:

20

Group:

Healthy Volunteers Group

Sample size:

干预措施:

不干预

干预措施代码:

Intervention:

Non-intervention

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津市

市(区县):

天津市

Country:

China

Province:

Tianjin

City:

Tianjin

单位(医院):

天津中医药大学第二附属医院

单位级别:

三甲

Institution/hospital:

Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

竖脊肌厚度

指标类型:

次要指标

Outcome:

Erector spinae thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

竖脊肌横截面积

指标类型:

次要指标

Outcome:

Cross sectional area of erector spinae

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

压痛阈值

指标类型:

次要指标

Outcome:

Pain threshold

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能连接

指标类型:

次要指标

Outcome:

Functional connectivity

Type:

Secondary indicator

测量时间点:

测量方法:

使用近红外脑功能成像测量,无需提取血液样本,测量过程无创、无痛

Measure time point of outcome:

Measure method:

Using fNIRS measurement, there is no need to extract blood samples, and the measurement process is non-invasive and painless

指标中文名:

β值

指标类型:

次要指标

Outcome:

β value

Type:

Secondary indicator

测量时间点:

测量方法:

使用近红外脑功能成像测量,无需提取血液样本,测量过程无创、无痛

Measure time point of outcome:

Measure method:

Using fNIRS measurement, there is no need to extract blood samples, and the measurement process is non-invasive and painless

指标中文名:

VAS评分

指标类型:

主要指标

Outcome:

VAS scores

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

竖脊肌腰段AEMG值

指标类型:

次要指标

Outcome:

AEMG value of lumbar segment of erector spinae

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

HbO2浓度均值

指标类型:

次要指标

Outcome:

HbO2 Mean concentration

Type:

Secondary indicator

测量时间点:

测量方法:

使用近红外脑功能成像测量,无需提取血液样本,测量过程无创、无痛

Measure time point of outcome:

Measure method:

Using fNIRS measurement, there is no need to extract blood samples, and the measurement process is non-invasive and painless

指标中文名:

竖脊肌腰段MF值

指标类型:

次要指标

Outcome:

MF value of lumbar segment of erector spinae

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

关节活动度

指标类型:

次要指标

Outcome:

Joint range of motion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

偏侧化指数

指标类型:

次要指标

Outcome:

Lateralization index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究的随机序列由专门的研究助理使用 SPSS 23.0 软件生成,随机数字被装入不透光的牛皮纸信封中保存。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence of this study was generated by a dedicated research assistant using SPSS23.0 software and the random numbers were stored in opaque kraft paper envelopes.

盲法:

由于干预方案的特殊性,本研究不对受试者与临床治疗者施盲,仅对评估人 员和数据分析人员施盲。

Blinding:

Due to the particularity of the intervention plan this study did not blind the subjects and clinical treatment personnel only the evaluators and data analysts.

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究者、监察员和数据管理员密切配合进行数据管理。主要涉及四方面:数据采集、录入、监查、数据管理。数据采集与录入是根据受试者的原始观察记录,保证将数据正确完整及时的载入CRF。数据采集采用CRF表进行原始记录,excel表格形式进行存储及统计分析;电子数据管理是根据fNIRS检测结果建立数据库,以供分析。 数据管理注意事项: (1)报告表上的内容不应涂改,如需更正,则将原数据划去,填上更正的数据,应由更正者签字并注明日期(只有数据录入员及其授权的人员可以修改CRF)。原数据被改正后仍要保证能看清。 (2)对于完成的病例报告表在数据录入员、数据管理员之间的传送应有专门的记录,收到时应有相应的签名,记录需妥善保存。 (3)研究文件(包括知情同意书、CRF等)的存档需由专人专柜并上锁保管,电子资料如fNIRS检测数据等需由专人(两人以上)保存。 (4)CRF上的修改必须有医生的签名、日期。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Researchers monitors and data managers work closely together to manage data. It mainly involves four aspects: data collection data entry monitoring and data management. Data collection and entry are based on the original observation records of the subjects to ensure that the data is correctly completely and timely loaded into the CRF. Data collection uses CRF tables for original records and Excel spreadsheets for storage and statistical analysis; electronic data management is to establish a database based on fNIRS test results for analysis. Data management precautions: (1) The content on the report form should not be altered. If correction is required the original data should be crossed out and the corrected data should be filled in. The corrector should sign and indicate the date (only data entry personnel and authorized personnel can modify CRF). The original data must still be clear after being corrected. (2) There should be a special record for the transmission of the completed case report form betwe

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统